الاتحاد الأوروبي - الإيطالية - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - hepatitis a virus (inactivated), hepatitis b surface antigen - immunization; hepatitis b; hepatitis a - vaccini - twinrix pediatrico è indicato per l'uso in bambini non-immuni, bambini e adolescenti da un anno fino a 15 anni compresi, che sono a rischio sia di infezione da epatite a che di epatite b.

إيطاليا - الإيطالية - AIFA (Agenzia Italiana del Farmaco)

glaxosmithkline s.p.a. - pertosse, antigene purificato, associazioni con tossoidi - pertosse, antigene purificato, associazioni con tossoidi

الاتحاد الأوروبي - الإيطالية - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - prodotti immunologici per felidae, - gatti - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

سويسرا - الإيطالية - Swissmedic (Swiss Agency for Therapeutic Products)

msd merck sharp & dohme ag - hepatitidis b viri antigenum adnr - sospensione iniettabile - hepatitidis b viri antigenum adnr 40 µg, aluminium 0.5 mg ut aluminii hydroxyphosphas sulfas amorphus, borax, natrii chloridum, aqua ad iniectabile q.s. ad suspensionem pro 1 ml corresp. natrium 3.5 mg. - immunizzazione attiva contro l'epatite b, in caso di dialisi e prädialysepatienten, che abbiano compiuto il 19. anni - vaccini

سويسرا - الإيطالية - Swissmedic (Swiss Agency for Therapeutic Products)

msd merck sharp & dohme ag - hepatitidis b viri antigenum adnr - sospensione iniettabile - hepatitidis b viri antigenum adnr 10 µg, aluminium 0.5 mg ut aluminii hydroxyphosphas sulfas amorphus, borax, natrii chloridum, aqua ad iniectabile q.s. ad suspensionem pro 1 ml corresp. natrium 3.5 mg. - immunizzazione attiva contro l'epatite b, che abbiano compiuto il 10. anni - vaccini

سويسرا - الإيطالية - Swissmedic (Swiss Agency for Therapeutic Products)

msd merck sharp & dohme ag - hepatitidis b viri antigenum adnr - sospensione iniettabile - hepatitidis b uomini antigenum adnr 40 µg, l'alluminio per aluminii hydroxyphosphas sulfas con l'amorfo, natrii boras, natrii chloridum, aqua ad iniectabilia q.s. la sospensione per 1 ml. - immunizzazione attiva contro l'epatite b, in caso di dialisi e prädialysepatienten, che abbiano compiuto il 19. anni - vaccini

سويسرا - الإيطالية - Swissmedic (Swiss Agency for Therapeutic Products)

msd merck sharp & dohme ag - hepatitidis b viri antigenum adnr - sospensione iniettabile - hepatitidis b uomini antigenum adnr 10 µg, l'alluminio per aluminii hydroxyphosphas sulfas con l'amorfo, natrii boras, natrii chloridum, aqua ad iniectabilia q.s. la sospensione per 1 ml. - immunizzazione attiva contro l'epatite b, che abbiano compiuto il 10. anni - vaccini

إيطاليا - الإيطالية - AIFA (Agenzia Italiana del Farmaco)

glaxosmithkline biologicals s.a. - vaccino epatitico b, antigene purificato - vaccino epatitico b, antigene purificato

الاتحاد الأوروبي - الإيطالية - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - prodotti immunologici per felidae, - gatti - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

إيطاليا - الإيطالية - AIFA (Agenzia Italiana del Farmaco)

msd italia s.r.l. - pneumococco, antigene purificato polisaccaridico - pneumococco, antigene purificato polisaccaridico